I think the size of the raising underwritten by a director, provides colour to recent comments by RH regarding active engagement with pharmaceutical partners in validating technology and the release of news flow around the nature of some of those relationships.
$2.5m would have been murky; $5m would have met expectations but $10m - as you say - makes a gutsy statement of progress in the technology.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.015(1.16%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.28 | $9.623K | 7.405K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2019 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 6848 | 1 |
View Market Depth
| Last trade - 10.00am 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |